Liquidnet Further Enhances Trading Platform with Acquisition of OTAS Technologies
Liquidnet, the global institutional trading network, today announced its acquisition of OTAS Technologies–a market-leading analytics platform that delivers actionable market intelligence and context directly to institutional traders and portfolio managers. OTAS’s industry-leading analytics and market insight, combined with Liquidnet’s Virtual High Touch decision-support trading platform, will help enhance the buy-side trader’s decision making process and give the trader more control over achieving best execution.
“The biggest challenges we hear from our buy-side Members today center on two things – finding the liquidity they need, and being able to sort through vast amounts of market information to access what’s relevant,” said Rob Laible, Liquidnet’s Global Head of Equity Strategy. “Our goal with this acquisition is to bring OTAS’s analytics into the Liquidnet platform and deliver market context directly to the trader at the point of execution.”
“The need to fill this void in the trader’s toolkit is further underscored by the added best execution requirements under MiFID II,” Laible continued. “We believe that a firm that incorporates OTAS analytics and our VHT platform into their trading strategy will be able to show a process and commitment to consistently achieving best execution for each and every order.”
The institutional trading landscape is changing rapidly as new regulations have firmly shifted responsibility for achieving and justifying best execution to the buy side. This can be a complicated process due to differing and changing market structures around the world, real-time market dynamics, market fragmentation, and varying liquidity profiles.
To help traders successfully manage this new landscape, Liquidnet launched Virtual High Touch (VHT) in November 2016–a completely new category of trader intelligence and decision-support tools for institutional traders that combines advanced data analytics, unique liquidity search tools, advanced algorithms, and real-time decision support. The idea behind VHT is that technology–when delivered in a meaningful, insightful and actionable way–can truly make the difference in terms of capturing and delivering alpha.
“Asset managers need a global partner that understands the complexities of market structure, compliance, and liquidity, and can bring to bear the tools and technology that are most relevant and impactful for the buy-side trader,” commented Tom Doris, Founder and CEO of OTAS Technologies. “By joining with Liquidnet, we are helping clients achieve their performance objective by delivering a more complete trader intelligence platform that can help address all parts of the trading process: finding liquidity; measuring potential trade impact; monitoring marketing conditions; and now supporting a best execution strategy on an order-by-order level.”
Launched in 2011, OTAS Technologies has established itself as a market leader in providing next-generation analytics and trader intelligence. More than 60 financial institutions currently access OTAS’s platform either directly or via one of its several channel partners, which include several OMS and EMS providers.
SenaHill Partners acted as the exclusive strategic and financial adviser for OTAS. SenaHill is a merchant bank focused on the financial technology (FinTech) sector.
Liquidnet is the global institutional trading network where more than 850 of the world’s top asset managers and other like-minded investors come to execute their large trades with maximum anonymity and minimum market impact. As the global leader in large block trading, Liquidnet provides access to unique trading opportunities in 44 markets across five continents. Liquidnet approaches every market with the same bold vision to provide a better, more efficient way to trade on a massive scale. It is this focus on size, combined with the strength of its network, disruptive technology, and commitment to transparency, that is revolutionizing the way equities and corporate bonds are traded. For more information, visit www.liquidnet.com and follow us on Twitter @Liquidnet.
© 2017 Liquidnet Holdings, Inc. and its subsidiaries. Liquidnet, Inc. is a member of FINRA/SIPC. Liquidnet Europe Limited is authorized and regulated by the Financial Conduct Authority in the UK, is licensed by the Financial Services Board in South Africa, and is a member of the London Stock Exchange and a remote member of the Warsaw Stock Exchange and SIX Swiss Exchange. Liquidnet Canada Inc. is a member of the Investment Industry Regulatory Organization of Canada and a member of the Canadian Investor Protection Fund. Liquidnet Asia Limited is regulated by the Hong Kong Securities and Futures Commission as a licensed dealer and a provider of automated trading services pursuant to the Securities and Futures Ordinance and is regulated by the Monetary Authority of Singapore as a Recognized Market Operator. Liquidnet Japan Inc. is regulated by the Financial Services Agency of Japan and is a member of JSDA/JIPF. Liquidnet Australia Pty Ltd. is registered with the Australian Securities and Investment Commission as an Australian Financial Services Licensee, AFSL number 312525, and is registered with the New Zealand Financial Markets Authority as a Financial Service Provider, FSP number FSP3781.
Marisha Mistry, +1-646-674-2248
Global Marketing & Communications
Streets Consulting for Liquidnet EMEA
Sybille Mueller, +44 (0)20 7959 2235
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
JANSSEN9.12.2017 18:21 | pressemeddelelse
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum